Adra S, Alabrach Y, Hashem A, Mahmoud A, Khalouf A, El-Khapery A
PLoS One. 2024; 19(9):e0309465.
PMID: 39236039
PMC: 11376511.
DOI: 10.1371/journal.pone.0309465.
Schleimer L, Kalvin H, Ellis R, Kingham T, Soares K, DAngelica M
Ann Surg Oncol. 2024; 31(10):6551-6563.
PMID: 39042229
DOI: 10.1245/s10434-024-15724-9.
Alaimo L, Moazzam Z, Endo Y, Lima H, Butey S, Ruzzenente A
Ann Surg Oncol. 2023; 30(7):4292-4301.
PMID: 36952150
DOI: 10.1245/s10434-023-13349-y.
Njei B, McCarty T, Mohan B, Fozo L, Navaneethan U
Ann Gastroenterol. 2023; 36(2):223-230.
PMID: 36864938
PMC: 9932867.
DOI: 10.20524/aog.2023.0779.
Liao C, Wang D, Jiang B, Huang L, Lin T, Qiu F
BMC Cancer. 2022; 22(1):1222.
PMID: 36443693
PMC: 9703772.
DOI: 10.1186/s12885-022-10323-x.
The influence of F-fluorodeoxyglucose positron emission tomography/computed tomography on the N- and M-staging and subsequent clinical management of intrahepatic cholangiocarcinoma.
Lin Y, Chong H, Song G, Zhang C, Dong L, Aye L
Hepatobiliary Surg Nutr. 2022; 11(5):684-695.
PMID: 36268256
PMC: 9577996.
DOI: 10.21037/hbsn-21-25.
Preoperative prediction of intrahepatic cholangiocarcinoma lymph node metastasis by means of machine learning: a multicenter study in China.
Huang T, Liu H, Lin Z, Kong J, Lin K, Lin Z
BMC Cancer. 2022; 22(1):931.
PMID: 36038816
PMC: 9426211.
DOI: 10.1186/s12885-022-10025-4.
DWI-based radiomic signature: potential role for individualized adjuvant chemotherapy in intrahepatic cholangiocarcinoma after partial hepatectomy.
Yang Y, Zou X, Zhou W, Yuan G, Hu D, Shen Y
Insights Imaging. 2022; 13(1):37.
PMID: 35244793
PMC: 8897536.
DOI: 10.1186/s13244-022-01179-7.
Mucin 1 promotes tumor progression through activating WNT/β-catenin signaling pathway in intrahepatic cholangiocarcinoma.
Song F, Chen F, Wu S, Hu B, Liang X, Yang H
J Cancer. 2021; 12(23):6937-6947.
PMID: 34729096
PMC: 8558653.
DOI: 10.7150/jca.63235.
Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress.
Bezrookove V, Patino J, Nosrati M, Desprez P, McAllister S, Soroceanu L
Cancers (Basel). 2021; 13(17).
PMID: 34503215
PMC: 8430987.
DOI: 10.3390/cancers13174405.
A Novel Prognostic Scoring System of Intrahepatic Cholangiocarcinoma With Machine Learning Basing on Real-World Data.
Li Z, Yuan L, Zhang C, Sun J, Wang Z, Wang Y
Front Oncol. 2021; 10:576901.
PMID: 33552957
PMC: 7855854.
DOI: 10.3389/fonc.2020.576901.
Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Saqub H, Proetsch-Gugerbauer H, Bezrookove V, Nosrati M, Vaquero E, de Semir D
Sci Rep. 2020; 10(1):18489.
PMID: 33116269
PMC: 7595101.
DOI: 10.1038/s41598-020-75578-5.
Telomeres and Telomerase in the Development of Liver Cancer.
In der Stroth L, Tharehalli U, Gunes C, Lechel A
Cancers (Basel). 2020; 12(8).
PMID: 32722302
PMC: 7464754.
DOI: 10.3390/cancers12082048.
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.
Arora M, Bogenberger J, Abdelrahman A, Leiting J, Chen X, Egan J
Cancer Chemother Pharmacol. 2020; 85(6):1063-1078.
PMID: 32440762
DOI: 10.1007/s00280-020-04079-z.
Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection.
Qu W, Zhou P, Liu W, Tian M, Jin L, Jiang X
Ann Transl Med. 2020; 8(7):487.
PMID: 32395531
PMC: 7210176.
DOI: 10.21037/atm.2020.03.23.
Renal metastasis from intrahepatic cholangiocarcinoma.
Matsumoto C, Imai K, Nakao Y, Itoyama R, Yusa T, Nakagawa S
Int Cancer Conf J. 2020; 9(2):66-71.
PMID: 32257756
PMC: 7109215.
DOI: 10.1007/s13691-019-00398-y.
Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study.
Luo J, Zheng J, Shi C, Fang J, Peng Z, Huang J
Medicine (Baltimore). 2020; 99(12):e19276.
PMID: 32195932
PMC: 7220404.
DOI: 10.1097/MD.0000000000019276.
Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies.
McGee E, Jackson S, Petrick J, Van Dyke A, Adami H, Albanes D
J Natl Cancer Inst. 2019; 111(12):1263-1278.
PMID: 31127946
PMC: 6910180.
DOI: 10.1093/jnci/djz103.
A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee J
Cancer. 2018; 125(6):902-909.
PMID: 30561756
PMC: 6402964.
DOI: 10.1002/cncr.31872.
SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance.
Yuan X, Li J, Coulouarn C, Lin T, Sulpice L, Bergeat D
Br J Cancer. 2018; 119(11):1358-1366.
PMID: 30420613
PMC: 6265288.
DOI: 10.1038/s41416-018-0338-9.
